Edwards Lifesciences Corp.

Company Overview

Edwards Lifesciences offers medical devices for critical care, vascular, and structural heart disease, and technologies to treat advanced CVD and other critical illnesses.

The company categorizes its products and technologies into four main areas: Transcatheter Aortic Replacement; Transcatheter Mitral and Tricuspid Therapies; Surgical Structural Heart; and Critical Care. The company operates in four reporting segments: the U.S., Europe, Japan and the Rest of the World. As of Dec. 31, 2021, the company had 15,700 employees worldwide.

The company manufactures heart valve systems for surgical and transcatheter therapies for heart valve replacement and repair. The company also offers transcatheter heart valves, including transcatheter aortic heart valves and their delivery for the nonsurgical replacement of heart valves, surgical heart valve therapy products and repair products, and minimally invasive monitoring systems, pressure-monitoring products, hemofiltration products and vascular stents.

Financial Highlights (FY 2024)

Company's Business Segments

• Transcatheter Aortic Valve Replacement : Transcatheter heart valve replacement technologies are designed for the minimally invasive replacement of Aortic heart valves.
• Transcatheter Mitral and Tricuspid Therapies : The development of transcatheter heart valve repair and replacement technologies designed to treat Mitral, Tricuspid valve diseases.
• Surgical Structural Heart : This segment includes innovations for cardiac surgery patients, products like RESILIA tissue, INSPIRIS RESILIA aortic valve, KONECT RESILIA which has VFit technology first pre-assembled, ready-to-implant, tissue valved conduit for complex combined procedures.
• Critical Care : This segment includes advanced Hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings. Edwards’ complete hemodynamic portfolio helps clinicians make proactive clinical decisions that can improve patient recovery. The portfolio includes the minimally-invasive FloTrac and Acumen IQ sensors, the noninvasive ClearSight, Acumen IQ cuffs, and the ForeSight noninvasive tissue oximetry sensor.